Publications

May 1987
Teaching Note

Eli Lilly and Co. (A) and (B), Teaching Note

By: William J. Bruns Jr.

Keywords: Pharmaceutical Industry

June 1999 (Revised October 1999)
Case

Eli Lilly, 1998 (A): Strategic Challenges

By: Michael Y. Yoshino and Thomas W. Malnight

Deals with key strategic challenges facing Eli Lilly, a highly successful U.S.-based drug company. View Details

Keywords: Problems and Challenges; Strategy; Pharmaceutical Industry

June 1998
Supplement

MBA Integrative Exercise: Competition & Strategy, April 1998 , Video

By: Carin-Isabel Knoop

Daniel Vasella, President of Novartis AG, discusses the situation in Indonesia and his ideas of what Suharto should do in the spring of 1998. Drummond Paris, Regional Pharma Head Asia/Pacific, Novartis AG, discusses the opportunities for Novartis in Indonesia and also... View Details

Keywords: Competitive Strategy; Pharmaceutical Industry; Indonesia

March 1993
Supplement

Burroughs Wellcome and AZT (C)

By: Willis M. Emmons III

Describes key developments relating to Burroughs Wellcome, AZT and other AIDS drugs, and the AIDS issue in general from late 1989 through 1992. Includes excerpts from Wellcome PLC's financial statements and updated statistics on AIDS in the United States. View Details

Keywords: Health Pandemics; Multinational Firms and Management; Financial Statements; Pharmaceutical Industry; United States

March 1993
Supplement

Burroughs Wellcome and AZT (B)

By: Willis M. Emmons III

Describes Burroughs Wellcome's response to protests over the pricing of its AIDS drug AZT in September 1989. Also presents short-term reactions by government officials, AIDS activists, and investors to Burroughs Wellcome's strategy. View Details

Keywords: Ethics; Health Pandemics; Multinational Firms and Management; Price; Crime and Corruption; Risk and Uncertainty; Business Strategy; Business and Community Relations; Business and Government Relations; Business and Shareholder Relations; Pharmaceutical Industry

March 1997
Teaching Note

Eli Lilly and Company: Innovation in Diabetes Care TN

By: Clayton M. Christensen and Bret J. Baird

Teaching Note for (9-696-077). View Details

Keywords: Pharmaceutical Industry

December 1998 (Revised September 1999)
Case

Novartis: Betting on Life Sciences

By: Ray A. Goldberg, Carin-Isabel Knoop and Srinivas Sunder

The merger of Ciba-Geigy and Sandoz produced genomic-based synergies for health care, agribusiness, and nutritional supplements. How to build on the strength of the individual divisions and provide synergies that would continue Novartis' leadership role is the question... View Details

Keywords: Mergers and Acquisitions; Business Divisions; Health Care and Treatment; Leadership; Product Positioning; Science-Based Business; Corporate Strategy; Pharmaceutical Industry

January–February 1994
Article

Financial Engineering at Merck

By: Timothy A. Luehrman

Keywords: Finance; Engineering; Health; Pharmaceutical Industry

Find at Harvard

November 18 2004
Article

Merck's Recall of Rofecoxib: A Strategic Perspective

By: Felix Oberholzer-Gee and Noorein Inamdar

Keywords: Health; Perspective; Pharmaceutical Industry

Find at Harvard

April 1999 (Revised May 2000)
Case

Pilgrim Drug Company

David Thomas takes his first sales management assignment and is faced with a sales rep revolt because of a possible territory reorganization. In addition, his sales division is performing well below the national average. Rewritten version of an earlier case. View Details

Keywords: Conflict Management; Salesforce Management; Performance; Pharmaceutical Industry

February 26, 2003
Article

Consumers' Reports on the Health Effects of Direct-To-Consumer Drug Advertising

By: Joel S. Weissman, David Blumenthal, Alvin J. Silk, Kinga Zapert, Michael Newman and Robert Leitman

Keywords: Customers; Advertising; Health; Pharmaceutical Industry

Find at Harvard

Read Now

01 Oct 2013
First Look

First Look: October 1

these issues, increase performance, and set a direction for the company, all while remaining true to the values of his family's business. Purchase this case: http://hbr.org/search/413086-PDF-ENG Harvard Business School Case 313-016 Shanghai View Details

Keywords: Sean Silverthorne

17 Mar 2009
First Look

First Look: March 17, 2009

Agreements in Bio-Pharmaceuticals Authors:Juan Alcácer, John Cantwell, and Michelle Gittelman Publication:In Location of Biopharmaceutical Activity, edited by Iain M. Cockburn and Matthew J. Slaughter. NBER, forthcoming. Abstract As the value chain of the View Details

Keywords: Martha Lagace

15 Feb 2012
Op-Ed

Occupy Wall Street Protestors Have a Point

unaffordable (which the pharmaceutical company Cipla did with HIV/AIDS drugs in Africa), and that brought housing to urban poor (one of building materials maker CEMEX's accomplishments in Mexico). Based on our research, we believe the... View Details

Keywords: by Joseph L. Bower, Herman B. Leonard & Lynn S. Paine

06 Aug 2001
Research & Ideas

Go Global—or No? Can You Make the Case?

Remember, we don't yet have the capability to serve the chemical and pharmaceutical industries here. There are still only 38 of us, and I estimate that building the support infrastructure we need just for domestic expansion could cost as... View Details

Keywords: by Walter Kuemmerle

November 2006
Case

Competitive Headaches (A): The Analgesic Wars

By: Dennis A. Yao

Addresses the problem of competing with a me-too consumer product. Focuses on Bristol-Meyers' 1975 strategy for introducing a competitor to Tylenol in the analgesic market. View Details

Keywords: Market Entry and Exit; Competition; Competitive Advantage; Pharmaceutical Industry; Pharmaceutical Industry

November 1999
Teaching Note

drugstore.com TN

By: Richard L. Nolan

Teaching Note for (9-300-036). View Details

Keywords: Pharmaceutical Industry; Pharmaceutical Industry